Kexing Biopharm Partners with IQVIA Holdings to Enhance Global Biopharmaceutical Development
- Kexing Biopharm partners with IQVIA to enhance global clinical development and regulatory approval for innovative drugs.
- The collaboration utilizes IQVIA's expertise to improve trial efficiency and accelerate access to international markets.
- This partnership marks a milestone in Kexing's ambition to become a leader in the biopharmaceutical industry.
Strategic Alliance to Propel Kexing Biopharm's Global Aspirations
Kexing Biopharm, a prominent biopharmaceutical company based in Shenzhen, has recently entered a strategic partnership with IQVIA, a global leader in clinical research services and healthcare analytics. Announced on August 11, 2025, this collaboration is poised to significantly accelerate Kexing's global clinical development, regulatory approval, and commercialization of innovative drugs and biosimilars, focusing particularly on Europe and other regulated international markets. This partnership aligns with Kexing’s ambitions for international expansion and enhances its capacity to bring high-quality pharmaceutical products to a broader audience.
The partnership leverages IQVIA's extensive expertise in global clinical trial design and regulatory strategies, which are essential for enhancing trial efficiency and expediting access to international markets. Kexing has already made substantial progress in its internationalization efforts, having successfully introduced several pharmaceutical products, including nab-paclitaxel, in key jurisdictions. By integrating advanced research and development capabilities with agile commercial execution, Kexing aims to fortify its position as a player in the international biopharmaceutical industry. The collaboration is expected to enhance Kexing’s global development capabilities and propel it toward becoming a leading biopharmaceutical innovator.
During the signing ceremony, Brian Mi, President of IQVIA Asia Pacific, commended Kexing's swift advancements in overseas commercialization and product innovation. He noted that this partnership not only creates new opportunities for both organizations but also emphasizes the importance of collaborative efforts in driving innovation in the biopharmaceutical sector. Kexing's CEO, Yanqing Zhao, echoed this sentiment, highlighting IQVIA's global clinical data resources, patient insights, and regulatory expertise as critical components in optimizing their development strategies and accelerating global registration timelines. This partnership marks a significant milestone for Kexing, reinforcing its commitment to scientific rigor and innovation in its quest for international market penetration.
Kexing Biopharm primarily focuses on the research, development, production, and commercialization of recombinant protein drugs and microecological preparations, addressing diverse therapeutic areas such as antiviral treatments, tumors, and autoimmune conditions. The company’s proactive approach in building cutting-edge biotechnology platforms for new proteins and nucleic acid drugs signals its intent to stay at the forefront of biopharmaceutical innovation.
The collaboration with IQVIA highlights a pivotal moment in Kexing Biopharm’s journey toward becoming a global leader in the biopharmaceutical industry, strengthening its capabilities to navigate regulatory landscapes and optimize clinical trials on an international scale.
